Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.WT

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by ProOrbiteon Jul 25, 2017 8:35am
191 Views
Post# 26504800

The first three (3) patients have demonstrated no recurrence

The first three (3) patients have demonstrated no recurrenceWOW...my prediction came true... This is awesome! Gongrats to all of you longs!
My previous post was spot on! No enrolment until full diclosure, news release on efficacy, AND THAT DISCLOSURE WAS TRULLY AWESOME!

"The first three (3) patients have demonstrated no recurrence of NMIBC lesions at the ninety (90) day cystoscopy analysis. One patient has presented with some reddened areas of the bladder wall, which will be biopsied at a future surgical date. Further clinical analysis will be conducted on the patients according to the approved clinical protocol.

 

An additional six (6) patients for the second part of the Study, are currently being enrolled, to be treated at a Therapeutic Dose of the PDC (0.70 mg/cm2) for NMIBC, using its novel PDT technology."

Bullboard Posts